In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
For the first half of the month, I didnt change my eating habits or exercise routine, and my weight fluctuated between 182-185 pounds
See my PepPal news coverage of the FDA February 2026 ruling for context on what changed
The information contained herein is not a substitute for and should never be relied upon for professional medical advice
According to the company's terms, payment does not guarantee the writing or dispensing of a prescription
Clinical trials have demonstrated that patients can lose between 10% to 20% of their body weight, depending on the medication and adherence to treatment